Momenta Pharmaceuticals Inc.
675 West Kendall Street
Cambridge,
MA 02142
United States - Map
Phone: 617-491-9700
Fax: 617-621-0431
Web Site: http://www.momentapharma.com
| Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. The company applies its technology for the development of generic versions of complex drug products, as well as for the discovery and development of novel drugs. Its product candidates include M-Enoxaparin, a generic version of Lovenox that is used to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; M356, a technology-enabled generic version of Copaxone, which is used for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; and M118, an anticoagulant. The company also involves in developing generic or biosimilar glycoprotein products. Momenta Pharmaceuticals has collaborations with Sandoz AG and Sandoz Inc. to develop and commercialize injectable enoxaparin. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals was founded in 2001 and is based in Cambridge, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Craig A. Wheeler , 48
Chief Exec. Officer, Pres and Exec. Director |
$
765.00K |
$
0 | Dr. Ganesh Venkataraman Ph.D., 42
Co-Founder, Chief Scientific Officer and Sr. VP of Research |
$
386.00K |
$
0 | Dr. Ram Sasisekharan Ph.D., 44
Co-Founder, Director, Member of Scientific Advisory Board and Member of Science Committee |
$
32.00K | N/A | Mr. Richard P. Shea , 57
Chief Financial Officer, Principal Accounting Officer, Sr. VP and Treasurer |
$
358.00K |
$
0 | Mr. Steven B. Brugger , 50
Chief Operating Officer |
$
484.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
